NATCO PHARMA | SANOFI INDIA | NATCO PHARMA/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 12.5 | 32.8 | 38.1% | View Chart |
P/BV | x | 4.1 | 14.7 | 28.2% | View Chart |
Dividend Yield | % | 0.7 | 2.8 | 25.4% |
NATCO PHARMA SANOFI INDIA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATCO PHARMA Mar-24 |
SANOFI INDIA Dec-23 |
NATCO PHARMA/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,108 | 8,278 | 13.4% | |
Low | Rs | 550 | 5,240 | 10.5% | |
Sales per share (Unadj.) | Rs | 223.3 | 1,238.0 | 18.0% | |
Earnings per share (Unadj.) | Rs | 77.5 | 261.8 | 29.6% | |
Cash flow per share (Unadj.) | Rs | 87.9 | 279.0 | 31.5% | |
Dividends per share (Unadj.) | Rs | 9.50 | 167.00 | 5.7% | |
Avg Dividend yield | % | 1.1 | 2.5 | 46.4% | |
Book value per share (Unadj.) | Rs | 326.8 | 411.2 | 79.5% | |
Shares outstanding (eoy) | m | 179.11 | 23.03 | 777.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.7 | 5.5 | 68.0% | |
Avg P/E ratio | x | 10.7 | 25.8 | 41.4% | |
P/CF ratio (eoy) | x | 9.4 | 24.2 | 38.9% | |
Price / Book Value ratio | x | 2.5 | 16.4 | 15.4% | |
Dividend payout | % | 12.3 | 63.8 | 19.2% | |
Avg Mkt Cap | Rs m | 148,509 | 155,659 | 95.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 5,250 | 3,706 | 141.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,988 | 28,511 | 140.3% | |
Other income | Rs m | 1,281 | 665 | 192.6% | |
Total revenues | Rs m | 41,269 | 29,176 | 141.4% | |
Gross profit | Rs m | 17,514 | 8,203 | 213.5% | |
Depreciation | Rs m | 1,868 | 396 | 471.7% | |
Interest | Rs m | 192 | 17 | 1,129.4% | |
Profit before tax | Rs m | 16,735 | 8,455 | 197.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,852 | 2,426 | 117.6% | |
Profit after tax | Rs m | 13,883 | 6,029 | 230.3% | |
Gross profit margin | % | 43.8 | 28.8 | 152.2% | |
Effective tax rate | % | 17.0 | 28.7 | 59.4% | |
Net profit margin | % | 34.7 | 21.1 | 164.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 40,235 | 31,314 | 128.5% | |
Current liabilities | Rs m | 9,728 | 25,347 | 38.4% | |
Net working cap to sales | % | 76.3 | 20.9 | 364.5% | |
Current ratio | x | 4.1 | 1.2 | 334.8% | |
Inventory Days | Days | 62 | 159 | 39.0% | |
Debtors Days | Days | 109 | 17 | 643.6% | |
Net fixed assets | Rs m | 28,634 | 15,714 | 182.2% | |
Share capital | Rs m | 358 | 230 | 155.7% | |
"Free" reserves | Rs m | 58,173 | 9,239 | 629.6% | |
Net worth | Rs m | 58,531 | 9,469 | 618.1% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 68,869 | 47,028 | 146.4% | |
Interest coverage | x | 88.2 | 498.4 | 17.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.6 | 95.8% | |
Return on assets | % | 20.4 | 12.9 | 159.0% | |
Return on equity | % | 23.7 | 63.7 | 37.3% | |
Return on capital | % | 28.9 | 89.5 | 32.3% | |
Exports to sales | % | 0 | 18.0 | 0.0% | |
Imports to sales | % | 9.5 | 25.2 | 37.7% | |
Exports (fob) | Rs m | NA | 5,143 | 0.0% | |
Imports (cif) | Rs m | 3,798 | 7,177 | 52.9% | |
Fx inflow | Rs m | 27,347 | 5,143 | 531.7% | |
Fx outflow | Rs m | 3,798 | 7,177 | 52.9% | |
Net fx | Rs m | 23,549 | -2,034 | -1,158.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 12,116 | 2,304 | 525.9% | |
From Investments | Rs m | -10,327 | 375 | -2,753.9% | |
From Financial Activity | Rs m | -2,469 | -8,783 | 28.1% | |
Net Cashflow | Rs m | -615 | -6,104 | 10.1% |
Indian Promoters | % | 49.6 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 24.3 | 28.4 | 85.4% | |
FIIs | % | 17.5 | 5.8 | 302.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 50.4 | 39.6 | 127.2% | |
Shareholders | 302,944 | 66,211 | 457.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare NATCO PHARMA With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Natco Pharma | Sanofi India | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.35% | -0.46% | 1.23% |
1-Month | 2.10% | -8.47% | -0.24% |
1-Year | 69.61% | -23.05% | 43.62% |
3-Year CAGR | 18.91% | -9.15% | 20.35% |
5-Year CAGR | 19.53% | -2.31% | 26.24% |
* Compound Annual Growth Rate
Here are more details on the Natco Pharma share price and the Sanofi India share price.
Moving on to shareholding structures...
The promoters of Natco Pharma hold a 49.6% stake in the company. In case of Sanofi India the stake stands at 60.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Natco Pharma and the shareholding pattern of Sanofi India.
Finally, a word on dividends...
In the most recent financial year, Natco Pharma paid a dividend of Rs 9.5 per share. This amounted to a Dividend Payout ratio of 12.3%.
Sanofi India paid Rs 167.0, and its dividend payout ratio stood at 63.8%.
You may visit here to review the dividend history of Natco Pharma, and the dividend history of Sanofi India.
For a sector overview, read our pharmaceuticals sector report.
After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.